The Outlook for JAK Inhibitors in Myelofibrosis
Ayalew Tefferi, MD, hematologist, Mayo Clinic, Rochester, Minnesota, discusses the outlook for JAK inhibitors for patients with myelofibrosis.
Clinical Pearls
Ayalew Tefferi, MD, hematologist, Mayo Clinic, Rochester, Minnesota, discusses the outlook for JAK inhibitors for patients with myelofibrosis.
- No JAK inhibitor can elicit PR or CR in myelofibrosis
- JAK inhibitors have good palliative value and are able to help a patient gain weight and shrink their spleen
- An oncologist wants to cure cancer or put it to sleep JAK inhibitors will never rise to that level
- There remains a need for pilot studies with innovative drugs that could potentially clear cancer
Recent Videos
Related Content
